Literature DB >> 19695457

Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left ventricular nonischemic cardiomyopathy.

Oscar Cano1, Mathew Hutchinson, David Lin, Fermin Garcia, Erica Zado, Rupa Bala, Michael Riley, Joshua Cooper, Sanjay Dixit, Edward Gerstenfeld, David Callans, Francis E Marchlinski.   

Abstract

OBJECTIVES: The aim of the study was to define the epicardial substrate and ablation outcome in patients with left ventricular nonischemic cardiomyopathy (NICM) and suspected epicardial ventricular tachycardia (VT).
BACKGROUND: Ventricular tachycardia in NICM often originates from the epicardium.
METHODS: Twenty-two patients with NICM underwent detailed endocardial and epicardial bipolar voltage maps and VT ablation for suspected epicardial VT. Eight patients with normal hearts and idiopathic VT served to define normal epicardial electrograms. Low-voltage regions were also assessed for wide (>80 ms), split, or late electrograms.
RESULTS: Normal epicardial bipolar voltage was identified as >1.0 mV on the basis of the reference population. Confluent low-voltage areas were present in 18 epicardial (82%) and 12 endocardial (54%) maps and were typically over basal lateral LV. In the 18 patients with epicardial VT on the basis of activation/pacemapping, the mean epicardial area was greater than the endocardial low-voltage area (55.3 +/- 33.5 cm(2) vs. 22.9 +/- 32.4 cm(2), p < 0.01). Epicardial low-voltage areas showed 49.7% wide (>80 ms), split, and/or late electrograms rarely seen in the reference patients (2.3%). During follow-up of 18 +/- 7 months, ablation resulted in VT elimination in 15 of 21 patients (71%) including 14 of 18 patients (78%) with epicardial VT.
CONCLUSIONS: In patients with NICM and VT of epicardial origin, the substrate is characterized by areas of basal LV epicardial > endocardial bipolar low voltage. The electrograms in these areas are not only small (<1.0 mV) but wide (>80 ms), split, and/or late, and help identify the substrate targeted for successful ablation. 2009 by the American College of Cardiology Foundation

Entities:  

Mesh:

Year:  2009        PMID: 19695457     DOI: 10.1016/j.jacc.2009.05.032

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  69 in total

Review 1.  Optimal ablation strategies for different types of ventricular tachycardias.

Authors:  Takumi Yamada; G Neal Kay
Journal:  Nat Rev Cardiol       Date:  2012-05-29       Impact factor: 32.419

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

3.  Impact of scar, viable myocardium, and epicardial fat on substrate identification of ventricular tachycardia in a case with nonischemic cardiomyopathy.

Authors:  Takeshi Sasaki; James Mudd; Charles Steenbergen; Menekhem M Zviman; Christopher F Miller; Saman Nazarian
Journal:  Pacing Clin Electrophysiol       Date:  2011-09-02       Impact factor: 1.976

4.  Assessing epicardial substrate using intracardiac echocardiography during VT ablation.

Authors:  Rupa Bala; Jian-Fang Ren; Mathew D Hutchinson; Benoit Desjardins; Cory Tschabrunn; Edward P Gerstenfeld; Rajat Deo; Sanjay Dixit; Fermin C Garcia; Joshua Cooper; David Lin; Michael P Riley; Wendy S Tzou; Ralph Verdino; Andrew E Epstein; David J Callans; Francis E Marchlinski
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-08-31

Review 5.  Sudden cardiac death in patients with nonischemic cardiomyopathy.

Authors:  Brian P Betensky; Sanjay Dixit
Journal:  Indian Heart J       Date:  2014-01-06

6.  Feasibility of directional percutaneous epicardial ablation with a partially insulated catheter.

Authors:  Ammar M Killu; Niyada Naksuk; Faisal F Syed; Christopher V DeSimone; Prakriti Gaba; Chance Witt; Dorothy J Ladewig; Scott H Suddendorf; Joanne M Powers; Gaurav Satam; Zdeněk Stárek; Tomas Kara; Jiří Wolf; Pavel Leinveber; Michal Crha; Miroslav Novák; Charles J Bruce; Paul A Friedman; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2018-07-14       Impact factor: 1.900

Review 7.  Ventricular tachycardias in the setting of cardiomyopathy: approaches to ablation.

Authors:  Nilesh Mathuria
Journal:  Tex Heart Inst J       Date:  2012

8.  Characterization of the arrhythmogenic substrate in ischemic and nonischemic cardiomyopathy implications for catheter ablation of hemodynamically unstable ventricular tachycardia.

Authors:  Shiro Nakahara; Roderick Tung; Rafael J Ramirez; Yoav Michowitz; Marmar Vaseghi; Eric Buch; Jean Gima; Isaac Wiener; Aman Mahajan; Noel G Boyle; Kalyanam Shivkumar
Journal:  J Am Coll Cardiol       Date:  2010-05-25       Impact factor: 24.094

9.  Prognostic significance of ventricular tachycardia clustering after catheter ablation in non-ischemic dilated cardiomyopathy.

Authors:  Francesco Santoro; Andreas Metzner; Leonie Scholz; Natale Daniele Brunetti; Christian-H Heeger; Andreas Rillig; Bruno Reissmann; Christine Lemeš; Tilmann Maurer; Thomas Fink; Osamu Inaba; Naotaka Hashiguchi; Karl-Heinz Kuck; Feifan Ouyang; Shibu Mathew
Journal:  Clin Res Cardiol       Date:  2018-10-22       Impact factor: 5.460

Review 10.  Advances in ablation of ventricular tachycardia in nonischemic cardiomyopathy.

Authors:  Nilesh Mathuria; Roderick Tung; Kalyanam Shivkumar
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.